» Articles » PMID: 32052005

Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia

Overview
Specialty Endocrinology
Date 2020 Feb 14
PMID 32052005
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Patients with congenital adrenal hyperplasia (CAH) require lifelong replacement therapy with glucocorticoids. Optimizing hydrocortisone therapy is challenging, since there are no established cortisol concentration targets other than the cortisol circadian rhythm profile. 17-hydroxyprogesterone (17-OHP) concentrations are elevated in these patients and commonly used to monitor therapy. This study aimed to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of cortisol using 17-OHP as a biomarker in pediatric patients with CAH and to assess different hydrocortisone dosing regimens.

Methods: Cortisol and 17-OHP concentrations from 30 CAH patients (7-17 years of age) receiving standard hydrocortisone replacement therapy (5-20 mg) twice (n = 17) or 3 times (n = 13) daily were used to develop a PK/PD model. Sequentially, simulated cortisol concentrations for clinically relevant 3- and 4-times daily dosing regimens were compared with cortisol and 17-OHP target ranges and to concentrations in healthy children.

Results: Cortisol concentration-time profiles were accurately described by a 2-compartment model with first-order absorption and expected high bioavailability (82.6%). A time-delayed model with cortisol-mediated inhibition of 17-OHP synthesis accurately described 17-OHP concentrations. The cortisol concentration inhibiting 50% of 17-OHP synthesis was 48.6 nmol/L. A 4-times-daily dosing better attained the target ranges and mimicked the cortisol concentrations throughout the 24-hour period than 3-times-daily.

Conclusions: A PK/PD model following hydrocortisone administration has been established. An improved dosing regimen of 38% at 06:00, 22% at 12:00, 17% at 18:00, and 22% at 24:00 of the daily hydrocortisone dose was suggested. The 4-times-daily dosing regimen was superior, avoiding subtherapeutic cortisol concentrations and better resembling the circadian rhythm of cortisol.

Citing Articles

Clinical Manifestations and Treatment Challenges in Infants and Children With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

Nokoff N, Buchanan C, Barker J J Clin Endocrinol Metab. 2025; 110(Supplement_1):S13-S24.

PMID: 39836622 PMC: 11749889. DOI: 10.1210/clinem/dgae563.


Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

Sarafoglou K, Auchus R J Clin Endocrinol Metab. 2025; 110(Supplement_1):S74-S87.

PMID: 39836617 PMC: 11749912. DOI: 10.1210/clinem/dgae759.


A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy.

Bindellini D, Michelet R, Aulin L, Melin J, Neumann U, Blankenstein O J Pharmacokinet Pharmacodyn. 2024; 51(6):809-824.

PMID: 38977635 PMC: 11579075. DOI: 10.1007/s10928-024-09934-7.


Model-Informed Target Morning 17α-Hydroxyprogesterone Concentrations in Dried Blood Spots for Pediatric Congenital Adrenal Hyperplasia Patients.

Stachanow V, Neumann U, Blankenstein O, Alder-Baerens N, Bindellini D, Hindmarsh P Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986563 PMC: 10051286. DOI: 10.3390/ph16030464.


Interpretation of Steroid Biomarkers in 21-Hydroxylase Deficiency and Their Use in Disease Management.

Sarafoglou K, Merke D, Reisch N, Claahsen-van der Grinten H, Falhammar H, Auchus R J Clin Endocrinol Metab. 2023; 108(9):2154-2175.

PMID: 36950738 PMC: 10438890. DOI: 10.1210/clinem/dgad134.